CD8A and cancer: The most common strategy exploited for the development of therapeutic cancer vaccines relies on the generation of endogenous cancer-specific cytotoxic CD8+ T cells (cytotoxic T lymphocytes, CTLs), due to their unique ability to kill cancer cells upon specific recognition (Farhood et al., 2018).